Literature DB >> 23024470

Production and Purification of Rabbit's Polyclonal Antibody Against Factor VIII.

Simin Sohrabi1, Azim Akbarzadeh, Dariush Norouzian, Ali Farhangi, Mehri Mortazavi, Mohammad Reza Mehrabi, Mohsen Chiani, Zahra Saffari, Soheil Ghassemi.   

Abstract

The attempt is made to produce recombinant factor VIII but the first step in producing such product is production and purification of rabbit's polyclonal antibody against factor VIII. The second and third steps involve monoclonal antibody and recombinant factor VIII production. Factor VIII is one of the most important coagulating factor where its deficiency leads to diseases like hemophilia type A or classic. It is an inherited disease. Previously, it was obtained through fractionation of blood plasma of blood donors. After processing, factor VIII could be used to manage such patients. Due to transfer of viral disease like hepatitis and HIV through factor VIII obtained by fractionation, high cost of production, insufficiency of the donors and the process of virus removal, thus production of factor VIII through recombinant technology can be useful and helpful. The reaction between antibody and antigen is one the most specific reaction; therefore, such reaction can be employed to identify factor VIII. Thereby, rabbits were injected several times with adjuvant-linked antigen to produce antibody. The antibody was separated from the blood sample, purified and used to identify factor VIII in the research.

Entities:  

Keywords:  Antibody purification; Factor VIII; Hemophilia; Polyclonal antibody; Quality control; Recombinant antibody

Year:  2011        PMID: 23024470      PMCID: PMC3210243          DOI: 10.1007/s12291-011-0142-2

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  17 in total

1.  Micromethods for the study of proteins and antibodies. I. Procedure and general applications of hemagglutination and hemagglutination-inhibition reactions with tannic acid and protein-treated red blood cells.

Authors:  A B STAVITSKY
Journal:  J Immunol       Date:  1954-05       Impact factor: 5.422

2.  Purification and characterization of factor VIII 372-Cys: a hypofunctional cofactor from a patient with moderately severe hemophilia A.

Authors:  D P O'Brien; J K Pattinson; E G Tuddenham
Journal:  Blood       Date:  1990-04-15       Impact factor: 22.113

3.  Factor VIII/von Willebrand factor protein. Galactose a cryptic determinant of von Willebrand factor activity.

Authors:  H R Gralnick
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

4.  Immunoaffinity purification of factor VIII complex.

Authors:  V S Hornsey; B D Griffin; D S Pepper; L R Micklem; C V Prowse
Journal:  Thromb Haemost       Date:  1987-02-03       Impact factor: 5.249

5.  Investigations and preparation of fibrinogencoated tan A/Das PC: Investigations and preparation of fibrinogen-coated tanned sheep red cells.

Authors:  P C Das
Journal:  J Clin Pathol       Date:  1970-03       Impact factor: 3.411

6.  Establishment of an ELISA system for determining soluble LAIR-1 levels in sera of patients with HFRS and kidney transplant.

Authors:  Weiming Ouyang; Jiangnan Xue; Jingmei Liu; Wei Jia; Zhouli Li; Xin Xie; Xuesong Liu; Jinlong Jian; Qi Li; Yong Zhu; Angang Yang; Boquan Jin
Journal:  J Immunol Methods       Date:  2004-09       Impact factor: 2.303

7.  Purification and characterization of a highly purified human factor VIII consisting of a single type of polypeptide chain.

Authors:  P J Fay; S I Chavin; D Schroeder; F E Young; V J Marder
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

Review 8.  Targeting thrombin--rational drug design from natural mechanisms.

Authors:  James A Huntington; Trevor P Baglin
Journal:  Trends Pharmacol Sci       Date:  2003-11       Impact factor: 14.819

9.  Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation.

Authors:  R Rieben; A Roos; Y Muizert; C Tinguely; A F Gerritsen; M R Daha
Journal:  Blood       Date:  1999-02-01       Impact factor: 22.113

10.  Development of a peptidomimetic ligand for efficient isolation and purification of factor VIII via affinity chromatography.

Authors:  Sebastian Knör; Alexey V Khrenov; Burkhardt Laufer; Evgueni L Saenko; Charlotte A E Hauser; Horst Kessler
Journal:  J Med Chem       Date:  2007-08-11       Impact factor: 7.446

View more
  1 in total

1.  Polyclonal antibodies for the detection of Trypanosoma cruzi circulating antigens.

Authors:  Edith S Málaga-Machaca; Alessandra Romero-Ramirez; Robert H Gilman; Sofía Astupiña-Figueroa; Noelia Angulo; Alejandro Florentini; Cinthya J Lovon-Luque; Remo A Gonza; Ada Del Carpio-Sanz; Inés Cabello; Rosina Camargo; Fernando Recuenco; Liliam A Barrueta-Soria; Manuela R Verastegui; Maritza Calderon; Holger Mayta
Journal:  PLoS Negl Trop Dis       Date:  2017-11-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.